TNF-α has been suggested as a potentially useful biomarker for the non-invasive stratification of patients with NAFLD [120], an hypothesis, however, warranting diagnostic accuracy studies to be verified and possibly to provide specific cut-offs of TNF-α to rule out or rule in the diagnosis of NASH or NAFLD-associated fibrosis. The gene discussed is TNF; the disease is metabolic dysfunction-associated steatotic liver disease.